• Nick Paul Taylor
• 17 Jun, 2019

Gene therapy specialist uniQure is considering selling up amid interest from large pharma buyers, according to Bloomberg. The report follows the revitalization of uniQure’s hemophilia B prospect and accompanying triple-digit stock price surge. According to unnamed sources, uniQure is working with advisers to assess options including a sale or partnership but is yet to decide which path to take.
Read more...